Australia's Indigenous people have high rates of chronic kidney disease and kidney failure. To define renal disease among these people, we reviewed 643 renal biopsies on Indigenous people across Australia, and compared them with 249 biopsies of non-Indigenous patients. The intent was to reach a consensus on pathological findings and terminology, quantify glomerular size, and establish and compare regional biopsy profiles. The relative population-adjusted biopsy frequencies were 16.9, 6.6, and 1, respectively, for Aboriginal people living remotely/very remotely, for Torres Strait Islander people, and for non-remote-living Aboriginal people. Indigenous people more often had heavy proteinuria and renal failure at biopsy. No single condition defined the Indigenous biopsies and, where biopsy rates were high, all common conditions were in absolute excess. Indigenous people were more often diabetic than non-Indigenous people, but diabetic changes were still present in fewer than half their biopsies. Their biopsies also had higher rates of segmental sclerosis, post-infectious glomerulonephritis, and mixed morphologies. Among the great excess of biopsies in remote/very remote Aborigines, females predominated, with younger age at biopsy and larger mean glomerular volumes. Glomerulomegaly characterized biopsies with mesangiopathic changes only, with IgA deposition, or with diabetic change, and with focal segmental glomerulosclerosis (FSGS). This review reveals great variations in biopsy rates and findings among Indigenous Australians, and findings refute the prevailing dogma that most indigenous renal disease is due to diabetes. Glomerulomegaly in remote/very remote Aboriginal people is probably due to nephron deficiency, in part related to low birth weight, and probably contributes to the increased susceptibility to kidney disease and the predisposition to FSGS. It is well known that Australia's Indigenous people are experiencing an epidemic of hypertension, type 2 diabetes, cardiovascular disease, renal disease, and renal failure. 1, 2 Renal disease has especially captured attention because of the high costs of treating subjects with renal replacement therapy (RRT). It is less well known that disease burden and outcomes differ markedly among Indigenous people across the country. [3] [4] [5] [6] [7] [8] [9] Figure 1 is a map of Australia by five categories of 'remoteness' as defined by the Accessibility/Remoteness Index of Australia (ARIA þ ) methodology. 10 Most of the interior of the continent and the north and west are remote or very remote (R/VR), as are the Torres Strait Islands. Today only about 25% of Indigenous people live in R/VR areas, while most live in urban or semiurban environments. Although the Torres Strait Islands are characterized as very remote, many Torres Strait Islander (TSI) people now live around population centers. Figure 1 also marks out Australia's states and territories, which were constituted without consideration of distribution of Indigenous people, but which bear most of the responsibility for, and costs of, RRT for their constituent populations. Table 1 shows the distribution of the 2006 Indigenous population by categories of remoteness of their usual place of residence, and by state/territory. 11 New South Wales has the largest Indigenous population, but most do not live remotely; Queensland has the next largest Indigenous population but only 19% live R/VR and almost all the Aboriginal people in Victoria and Tasmania live near population centers. However, 480% of Aboriginal people in the Northern Territory (NT) and about 42% in Western Australia live in R/VR areas.
Assignment of Indigenous status for Australia's census is through self report, and it embraces very heterogeneous populations. Aboriginal people and TSI are distinct groups, of Micronesian and Melanesian descent, respectively, with different cultures, lifestyles, diets, body habitus, and health status. Moreover, mainland Aboriginal Australians are themselves very heterogeneous in location, languages, nonIndigenous admixture, lifestyle, socioeconomic status, body habitus, health, life expectancy, and access to, and utilization of, services. All documented health parameters, including birth weights, hospitalization rates, and perinatal, infant and adult mortality, are worse in mainland Aborigines living in R/VR areas than in those living less remotely.
Cass et al. 12, 13 described vast variation by region and remoteness in the incidence of Indigenous people beginning RRT from 1993-1998 (Figure 2) , and confirmed it again, 10 years later.
14 There was a great, though variable, excess in RRT incidence in Indigenous people in remote and very remote areas, and much lower rates for those living closer to population centers. The gradient in RRT correlated strongly and directly with level of socioeconomic disadvantage, of which low birth weight is one indicator. 13 Variation by remoteness has more recently been reported by the Australian Institute of Health and Welfare, from ANZDATA information; 15 that report also defined an excess of females among T o r r e s S t r a i t K a t h e r i n e M t I s a J a b i r u A p u t u l a K a l g o o r l i e T e n n a n t C r e e k Figure 2 | Standardized incidence rates of end-stage renal disease resulting in renal replacement therapy in Indigenous Australians in selected regions, 1993-1998. Note: Standardized incidence ratio. Index population for standardization was the total Australian resident population. Source: Adapted with permission, Cass et al. Figure 3 shows the very different RRT incidence rates by state/territory, ranging from less than twice that of nonIndigenous Australians (about 110 per million per year) to a 14-fold increase. 2 These differential rates, which are directly linked to RRT treatment costs on a population basis, largely reflect the different proportions of Indigenous populations by remoteness of residence, as noted in Table 1 .
Awareness of the excess of kidney disease in Aboriginal people was first heightened in the Top End of the NT and in Central Australia, and renal biopsies were frequently performed to define the processes. 17, 18 A high frequency of subjectively assessed glomerulomegaly was described, along with mesangial proliferation and focal sclerosis. 17, 18 Glomerulomegaly was later confirmed by formal measurements, and again shown to associate with focal segmental glomerulosclerosis (FSGS). 19, 20 However, the definition of some of the morphological features and their relationships to possible 'diagnoses' have been uncertain, and practitioners in other jurisdictions have questioned the applicability of these findings to the Indigenous populations they serve. We therefore organized a review of all Indigenous renal biopsies across Australia. Its objectives were to reach consensus on pathological findings and terminology, quantify glomerular size, and establish and compare regional biopsy profiles.
RESULTS
Among 1026 biopsies retrieved and reviewed, 735 were from indigenous people. Of these, 38 were of transplanted kidneys, 20 were second or subsequent biopsies of kidneys in the same person, and 24 contained no glomeruli or were otherwise nonevaluable. The final Indigenous series consisted of 653 eligible biopsies, whose light microscopic findings were evaluated by our expert panel of nephropathologists (Table 2 and Materials and Methods). Photographs or reports of immunofluorescent examinations were available for 577, and 497 had electron microscopy studies.
Ten biopsies from Pacific Islanders and 10 of unknown ethnicity, were excluded. There were 249 evaluable nontransplant biopsies on non-Indigenous people, described here; 224 had reports of immunofluorescence, and 240 had electron microscopy photographs and/or reports. Table 3 shows the number of evaluable biopsies in Indigenous people by state/territory, by categories of remoteness, and by Aboriginal, TSI, or TSI/Aboriginal designation. Remoteness classification was lacking for 33. Most biopsies were from the NT (Top End and Central Australia) and Queensland, which included all TSI people, with more modest numbers from Western Australia and South Australia, only five from New South Wales, and none from the Australian Capital Territory. Two Indigenous biopsies were identified in Victoria in 2011, but time did not permit ethics approvals for their inclusion in this review. Most Aboriginal biopsies were from people living in R/VR areas, and only 22 were from Aboriginal people living in or near major cities. There were 73 biopsies from TSI people and 12 from people of mixed TSI/Aboriginal descent.
Indigenous biopsy findings were analyzed in three groups, Aboriginal R/VR, Aboriginal non-remote (from major cities, inner regional areas, and outer regional areas), and as TSI. All were compared with findings in the non-Indigenous biopsies. Data from 11 people of mixed TSI/Aboriginal descent, who had remoteness classification, were included in analyses of both the Aboriginal and TSI groups, which did not substantially change the group results. Figure 4a shows estimates of the population-based frequencies of biopsies by these categories, using the total number of biopsies as the numerator and the regional 2006 census populations as denominators. This is not an annual estimate because biopsies were gathered from 1982 to 2005, and the Indigenous population has more than doubled over that interval. Nonetheless, with the same assumptions applied to each group, the relative ranking is informative. The figure demonstrates, on an exponential scale, the great excess of biopsies in people from R/VR areas, and a predominance of females in that group, while Aboriginal people 22 Aboriginal R/VR: derived, using average rates from McDonald et al. 23 and Rowley et al.
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closer to population centers had much lower biopsy rates and no female excess. Relative to the population-adjusted frequency of biopsies in non-remote Aboriginal people, there was a 6.6-fold greater biopsy frequency in TSI people and a 16.9-fold increase in biopsies from R/VR Aboriginal people. This ranking is similar to that of RRT incidence rates (Figure 4b ). Rates of overt albuminuria ascertained from limited localized studies in each region [21] [22] [23] [24] have similar rankings (Figure 4c ). Table 4 shows some demographic and clinical features of biopsy subjects. An excess of females among biopsied R/VR Aboriginal people was confirmed, and was also seen in TSI people. This contrasts with a male excess in less-remoteliving Aboriginal people, like that in non-Indigenous people. Median age at biopsy was lowest in R/VR Aboriginal people, and in TSI and non-remote Aboriginal people was more like those of non-Indigenous people. Indigenous people were more frequently identified as diabetic at the time of biopsy. They more often had nephrotic range proteinuria, renal insufficiency, and renal failure at biopsy than nonIndigenous people. Table 4 also shows some of the light microscopic morphological biopsy features. The median number of glomerular profiles per biopsy was about 14. The measured average glomerular tuft volume in non-end-stage kidneys was significantly larger in R/VR Aboriginal people than in the other three groups. The values were unchanged when restricted to biopsies with X4 glomerular profiles (95% of non-Indigenous and 91% of Indigenous biopsies). 25 Almost all Indigenous biopsies had mesangiopathic change ( Table 2 , including items no. 2, no. 3) and more often had segmental glomerular tuft sclerosis (items no. 12-18) than nonIndigenous biopsies. Most biopsies had interstitial inflammation and fibrosis with tubular atrophy and loss (items no. 23, no. 24, no. 28, no. 29). Crescents, largely cellular and fibrocellular, were present in substantial proportions of biopsies, and involved more than 10% of glomeruli (item no. 9). Most had vascular changes (items no. [31] [32] [33] [34] [35] . Indigenous people more often had end-stage kidneys at biopsy.
The table also shows the final assessments, derived from the experts reviewers' 'diagnoses' and the final collation of individual morphological variables. Leading assessments among R/VR Aboriginal biopsies were diabetic change, mesangiopathic glomerulonephritis (GN) (without IgA), and IgA nephropathy. Indigenous biopsies more often had diabetic changes, with the highest proportions in non-remoteliving Aborigines and TSI. However, diabetic change was found in fewer than half the Indigenous biopsies. The proportion of biopsies with a diagnosis of FSGS was highest in biopsies from R/VR Aboriginal people. IgA nephropathy was well represented in all the indigenous groups, although in lower absolute proportions for R/VR Aboriginal people, among whom 14% had crescents. Substantial numbers of Indigenous people had diffuse proliferative GN (40-60% with crescents), which included much higher proportions with post-infectious GN. The constitution of the infiltrates associated with interstitial nephritis was similar in all groups: with lymphocytic/histiocytic cells always present, while about 50% also had plasma cells, and about 30% had eosinophils/ polymorphonuclear cells. Sixteen Indigenous people, all from R/VR areas, had amyloid in their kidney biopsies, which, when (infrequently) specified, was the amyloid light chain type. The proportions with membranous GN were lower in the R/VR Aboriginal series and TSI biopsies than in nonIndigenous biopsies. Indigenous people had higher proportions of biopsies with multiple 'diagnoses' , excluding cases of secondary FSGS with a specified underlying condition, of which most fell into four major categories-diabetic nephropathy plus post-infectious GN (n ¼ 21), diabetic nephropathy plus IgA nephropathy (n ¼ 13), diabetic nephropathy plus interstitial nephritis (n ¼ 10), and diabetic nephropathy plus diffuse proliferative GN (n ¼ 6). Figure 5 demonstrates the higher mean glomerular volumes (MGV) in biopsies of R/VR Aboriginal people compared with the other study groups. Figure 6 shows that among mutually exclusive groups of 'diagnoses' in non-endstage kidneys in R/VR Aboriginal people, average mean glomerular volumes in decreasing rank order were mesangiopathic changes alone, FSGS (with similar values for secondary and primary forms: means 4.1, confidence interval 3.5-4.7 vs 3.8, confidence interval 3.1-4.5) and diabetic nephropathy. The average MGV was also elevated in people with IgA nephropathy without FSGS, but the numbers were smaller. Table 5 shows that, with retrospective application of the 2010 classification of Thijs et al., 26 the major classes of diabetic nephropathy in all subjects groups were severe mesangial expansion (Class IIB) and advanced diabetic sclerosis (Class IV), with substantial proportions with diabetic nodular sclerosis. Table 6 and 7 show classifications of FSGS. 27 Cases of secondary FSGS, further defined in the legend of the table, outnumbered apparent primary FSGS in Indigenous people. The major histological category in both primary and The Columbia classification. 27 An assignment of secondary FSGS was given if any of the following clinical-pathologic conditions were present: diabetes mellitus, diabetic nephropathy, IgA nephropathy, lupus nephritis, thin membrane nephropathy, immune complex glomerulonephritis, pyelonephritis, reflux nephropathy, familial nephritis, or morbid obesity. The remaining biopsies were assigned as primary FSGS. Heavy proteinuria: albumin creatinine ratio X300 g/mol or urinary protein: dipstick X3+ or X3 g/day or X3 g/l, or stated in history.
secondary forms was the unspecified type, followed by the perihilar variant. Applying the proportions of diagnoses/assessments to the relative frequencies of biopsies on a population basis, there was a great excess of most leading biopsy findings among R/VR Aborigines, and a considerable excess in TSI people, as shown in Figure 7 .
DISCUSSION
This is the first nationwide perspective on renal biopsies in Australian Indigenous people. It shows marked heterogeneity of biopsy rates among them, and similarities as well as differences in morphological findings. Among R/VR Aboriginal people, there was a striking relative and absolute excess of biopsies, a female predominance, a younger age at biopsy, and larger glomeruli, compared with other Indigenous as well as non-Indigenous biopsies. There was a relative excess of biopsies in TSI people and a female predominance, but an older age at biopsy. Among the many fewer non-remote Aboriginal people with biopsies, there was no female excess and their ages at biopsy were higher, both more aligned to the non-Indigenous biopsy series.
The biopsy frequencies and gender distributions among the Indigenous groups approximately parallel their RRT rates and patterns. They are also compatible with communitybased distributions of overt albuminuria found in a very limited number of localized studies in the relevant groupings, (all of which contrast with 0.6% prevalence in adult nonIndigenous Australians, without a female dominance). 28 These are reassuring synergies between community-based disease frequency, biopsy rates, and terminal renal failure.
The absolute numbers and the population-based rates of biopsies in the states and territories reflect to a large extent the characteristics of their Indigenous populations and the variations of the distributions of their Aboriginal people by remoteness. This helps explain the different impressions of nephrologists in the various states/territories about the frequency and nature of renal disease they see in Indigenous people.
All the usual changes and 'diagnoses' were represented in Indigenous people in this biopsy series. Notable in all three Indigenous groups were the high, though variable, proportions of diabetics, more advanced renal disease at biopsy, their higher frequency of diabetic nephropathic changes, of segmental glomerular tuft injury, and of post-infectious GN. Proportions of biopsies with IgA nephropathy, other forms of mesangiopathic GN, and membranous GN were not higher in R/VR Aboriginal and TSI biopsies than in non-Indigenous people. However, as we have emphasized (Figure 7 ), wherever the renal disease burden and the biopsy rates are high, the absolute number of biopsies with any finding of substantial frequency represents a population-based excess.
We cannot comment on genetic determinants of renal disease among Indigenous people, although genomic studies have begun. However, the major drivers of excess renal disease are potentially modifiable risk factors, such as intrauterine growth retardation and low birth weight, poor nutrition in infancy, childhood, and adult life, high levels of adult body mass index and diabetes, and the burden of infections and inflammation. [29] [30] [31] These are generally worse in Aborigines from R/VR areas: e.g., the frequency of low birth weight is still increased 2-3-fold, 32 and, in the NT, was present in about one-third of births 40 years ago, 30, 31, 33 when susceptibility was established in current biopsy subjects. Nonremote Indigenous people have higher birth weights, though still about 100 g short of the non-Indigenous Australian norm, 32 and high levels of diabetes, 21 while TSI people have largely normal birth weights, 9 but very high levels of adult obesity and diabetes. 9, 22 Our findings support the high frequency of glomerulomegaly previously documented in Aboriginal biopsies from Top End NT 19 and extend the observation to other Aborigines in R/VR areas, as described by subjective assessments many years ago. 17 Specific proliferative diseases aside, glomerular enlargement is thought to be driven by compensatory hypertrophy in the setting of lower nephron numbers and/or by other hypertrophic stimuli such as overweight or obesity, the metabolic syndrome, and diabetes and perhaps inflammation. 34 We recently described enlarged glomeruli at autopsy in kidneys of people without obvious renal disease, in the presence of lower nephron number, low birth weight, and obesity. [34] [35] [36] [37] [38] [39] Furthermore, in that autopsy series, we found that R/VR Aboriginal people without renal disease had, on average, lower nephron numbers and higher glomerular volumes than regional non-Aboriginal controls, a difference that was probably driven by the lower birth weights of the Aboriginal group. 40 We have also described an association of lower birth weights with renal disease in the R/ VR community setting. 30, 31 Thus glomerulomegaly in biopsied R/VR Aboriginal people probably represents compensatory hypertrophy in the presence of congenital nephronopenia related to low birth weight and intrauterine growth restriction, with variable superimposition of postnatal effects of body size, metabolic disorders, and infection/ inflammation. This is compatible with Brenner's nephropathy of oligonephronia in a multideterminant or 'multihit' model of renal disease in a high-risk environment. 41, 42 Obesity is less likely to be a primary driver of glomerulomegaly in this setting, for in some R/VR communities rates of overweight and obesity are considerably below those for non-Indigenous Australians. 43, 44 Nephron deficiency is less likely to contribute to glomerulomegaly and renal disease in non-remote Aboriginal people and still less in TSI people, who have higher birth weights, but higher rates of overweight, diabetes, and the metabolic syndrome.
The association of glomerular enlargement with FSGS demonstrated in the R/VR Aboriginal groups is also consistent with our previous observation in a smaller number of Top End Aboriginal biopsies. 20 Hughson et al. 45 have described a similar sequence with FSGS in biopsies of African Americans. Glomerular tuft injury might be mediated through deficient podoctye coverage of glomerular basement membrane as glomeruli enlarge, as observed in a model of nephronopenia by Kriz, 46 with the largest volumes, demonstrated in biopsies with mesangial change only, representing the earliest phase of injury, and FSGS a more advanced stage. We suggest that glomerular enlargement underlies excessive susceptibility to injury in the presence of other predisposing factors. Glomerulomegaly and its accompaniments will be further addressed in subsequent manuscripts.
Excess renal disease in Indigenous Australians is commonly attributed to type 2 diabetes. 2 However, fewer than half the Indigenous biopsy subjects were recorded as diabetic at biopsy, and not all their biopsies showed diabetic change. In fact, among the great excess of biopsies among R/VR Aboriginal people, only one quarter had definitive diabetic change. Although rates of diabetes are high, and many Indigenous people have acquired the diagnosis by age of 45 years, such a history does not mean that diabetic nephropathy is the primary cause of renal disease in a given patient. In fact, community-based studies in R/VR Indigenous people that show substantial prevalence of proteinuria in people without diabetes, 21, 22, 29, 47 demonstrate that proteinuria/ albuminuria appear at higher rates and earlier in life than diabetes, 47, 48 and predict, often by many years, the later development of diabetes. 49 Thus, albuminuria seems to be part of the hemodynamic/metabolic/renal syndrome, of which diabetes is a later and variable element. We acknowledge, however, that most diabetic patients with a clinical picture compatible with diabetic nephropathy do not undergo renal biopsies to confirm a diagnosis, and concede that diabetes facilitates and accelerates progression of kidney disease of most causes.
High levels of immune complex and post-infectious disease are compatible with the persistent and recurrent infections and the elevated inflammatory markers in these environments. 23, [50] [51] [52] [53] Excessive accumulation of immune complexes and other deposits and/or their defective clearance could also contribute to, or result from, the mesangiopathy that accompanies glomerular enlargement, at least in the nephron deficiency model. 46 The female excess in renal disease, seen in the RRT population, in community screening programs and now in biopsies in R/VR Aboriginal and TSI people, is not completely understood. Partial explanations might lie in the lower nephron endowment in females (about 17% fewer nephrons 54 ), their lower birth weights, higher body mass indexes, and greater central fat deposition, higher rates of diabetes until mid life, and perhaps the effects of pregnancy.
There are many limitations to this study. The consolidation of non-remote Aboriginal people into only one category obscures potential additional differences. Deficient Indigenous assignment could influence case ascertainment, as well as population denominators. Nephrologists' recall is undoubtedly incomplete, and the designation of 'at least half Indigenous' (see Methods) is precarious. Furthermore, levels of awareness and ascertainment of preterminal renal disease have varied by region and over time, as have availability of nephrology expertise and philosophies about biopsies. For example, the first spate of biopsies in the Top End of the NT was driven by need to define the lesions. More recently, biopsies have often been limited to people in whom unusual findings might change management, beyond general renal protection and metabolic and blood pressure control. And, as already noted, diabetics with renal disease are usually not biopsied.
Nonetheless important facts are exposed for the first time by this series. The variations in biopsy rates and findings resonate with the population-based variations in clinical renal disease in Indigenous people across the country. These are probably explained by regional differences in stages in the epidemiological and health transitions, in environmental and socioeconomic circumstances and in genotype and genetic admixture, and are expressed in variable accentuation of frequency of most of the common or garden variety of renal morphologic changes. The greatest absolute reduction in clinical renal disease and RRT will be through intensive targeting of risk factors in R/VR Aboriginal people and in TSI people.
MATERIALS AND METHODS
All nephrologists in Australia were invited to participate, through identification of Indigenous people who had undergone kidney biopsy and through participation in biopsy reviews. The major pathology laboratories in each region were likewise requested to identify Indigenous renal biopsies where possible. Ethical review boards at each clinical center and laboratory, as well as the participating academic centers, and their Indigenous subcommittees, approved the study.
The review was restricted to people considered to be at least half Indigenous. Slides from contemporaneous biopsies on non-Indigenous people were also retrieved in an approximate ratio of one per three Indigenous biopsies. Demographic data were derived from hospital databases or biopsy referral forms. Clinical summaries were taken from biopsy referral sheets; the detail was sometimes very deficient.
The expert review group consisted of five international nephropathologists (ABF, JPD, MDH, PSK-S, and RS). They, and other interested persons, met for 4-week-long meetings over a period of 3 years. A data collection form (Table 2 ) was developed through a process of progressive modification as findings dictated. The panel, initially blinded to ethnicity, demographic and clinical history of the biopsied subjects, recorded findings on light microscopic review of the slides, and their tentative assessments. The reviews were conducted either in committee or discussed by the whole committee following review by individual experts. The panel later reviewed their assessments as photographs and reports of immunofluorescence and electron microscopy studies became available. The presence, localization, and nature of immune complex deposits were determined and glomerular basement membranes examined. Finally, diagnoses were refined in the context of an individual's information from all sources, including available clinical data.
In a subsequent phase, glomerular tuft and corpuscle volumes in each biopsy were estimated, as previously described, 19 through application of the Weibel and Gomez formula to the average measurement of the areas of all available glomerular profiles on a given section. Later steps included formal measurement of glomerular sclerotic index, interstitial fibrosis, and glomerular basement membrane thickness, with techniques and the findings described in later manuscripts.
Statistical analyses were conducted using Stata Statistical Software: Release 11 (StataCorp, College Station, TX). Summary data are presented as means with s.d.'s or as category percentages. Means were compared using the t-test, accounting for unequal variance as necessary. Proportions were compared using the w 2 or the Fisher's exact tests.
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